Evidence map›Paper›PMID 40575184›Full record

ArticleJAC-antimicrobial resistance2025

Rapid valve sterilization with meropenem plus ceftolozane/tazobactam combination therapy for

Valliammai Alaguvel, Anuj K Khetarpal, Allen Jankeel, Wendy A Tapia-Cano, Gabriela Martinez, Arianna Lorenzana, Zoe Hsiao, Warren Rose, George Sakoulas, Erlinda R Ulloa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valliammai AlaguvelDepartment of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.
Anuj K KhetarpalDepartment of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.
Allen JankeelDepartment of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.
Wendy A Tapia-CanoDepartment of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.
Gabriela MartinezDepartment of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.
Arianna LorenzanaDepartment of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.
Zoe HsiaoDepartment of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.
Warren RoseSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID https://orcid.org/0000-0001-5012-5993
George SakoulasCollaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.ORCID https://orcid.org/0000-0002-6063-6217
Erlinda R UlloaDepartment of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.ORCID https://orcid.org/0000-0002-0330-278X

Funding

Institute for Clinical and Translational ScienceUM1TR004927 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI DAN M COOPER, Eric J. Vilain · 2024 to 2026
$12.2M
Beta-Lactamase Inhibitors Sensitize Multidrug-Resistant Gram-negative Pathogens to Innate Immune ClearanceK08AI151253 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI ULLOA, ERLINDA ROSE · 2020 to 2024
$1.0M
NCATS NIH HHS UM1 TR004927NIAID NIH HHS K08 AI151253
6 · The paper itself

Abstract

Background: Methods: We report a case of Results: Meropenem plus ceftolozane/tazobactam combination therapy successfully bridged the patient to cardiac surgery, achieving rapid microbiological clearance and sterile intraoperative valve cultures. While checkerboard assays showed additivity, time-kill assays with subtherapeutic antibiotic concentrations did not demonstrate synergy in standard media. However, significant synergy was observed in human whole blood and biofilm environments, with modestly improved activity in the SEV model. Conclusions: The combination of meropenem and ceftolozane/tazobactam demonstrates promising synergy in physiologically relevant conditions, offering a potentially safer alternative for treating

Identifiers

PMID40575184
PMCPMC12198497

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.